Oxford Biomedica announces that Sio Gene Therapies intends to cease the license agreement for gene therapy programme in Parkinson’s disease
This is a partner product. Visit the relevant partner website for further information. Read More
Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the US with Homology Medicines as 20% owner
Oxford Biomedica and Homology Medicines to establish Oxford Biomedica Solutions LLC, a new US-based AAV manufacturing and innovation business Homology Medicines to receive $130 million from Oxford Biomedica to continue to advance its three clinical programmes and genetic medicines platform Oxford Biomedica to invest $50 million to fund… Read More
John Dawson to retire from Oxford Biomedica
Oxford, UK – 17 January 2022: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group” or “the Company”) a leading gene and cell therapy company, today announces that, after more than 13 years of service, John Dawson, Chief Executive Officer, has signalled to the Board his intention to retire from… Read More
Oxford Biomedica Signs Licence and Supply Agreement with Cabaletta Bio for LentiVector® Platform
Oxford, UK – 5 January 2022: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces that it has signed a new License and Supply Agreement (LSA) with Cabaletta Bio, Inc. (Nasdaq: CABA) (“Cabaletta Bio”), a Philadelphia, USA-based clinical-stage biotechnology company… Read More
John Dawson awarded CBE in the Queen’s New Year Honours List
Oxford, UK – 31 December 2021: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, is pleased to announce that the Group’s Chief Executive Officer John Dawson has been awarded a CBE (Commander of the Order of the British Empire) for services… Read More
Oxford Biomedica Appoints Catherine Moukheibir as Non-Executive Director
Oxford, UK – 14 December 2021: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announces the appointment of Ms Catherine Moukheibir to the Board as an Independent Non-Executive Director with effect from today. Ms Moukheibir has extensive international experience in finance, capital… Read More
Oxford Biomedica updates and extends Commercial Supply Agreement for Manufacture of Lentiviral Vectors
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory… Read More
Oxford Biomedica Signs Licence & Supply Agreement with Arcellx, Inc. for LentiVector® Platform for CAR-T Therapeutics
Oxford, UK – 13 December 2021: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces that it has signed a new Licence and Supply Agreement (“LSA”) with Arcellx, Inc. (“Arcellx”), a Gaithersburg MD.-based biotechnology company developing novel, adaptive and controllable… Read More
Boehringer Ingelheim Exercises Option
Oxford Biomedica Announces that Boehringer Ingelheim has Exercised Option Relating to a Novel Gene Therapy Treatment for Cystic Fibrosis Oxford, UK – 19 October 2021: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces that Boehringer Ingelheim has exercised its option… Read More
Oxford Biomedica announces strategic investment by Serum Life Sciences Ltd
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory… Read More
Interim results for the six months ended 30 June 2021
Oxford Biomedica delivers record first half results Oxford, UK – 22 September 2021: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: Oxford Biomedica), a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2021. John Dawson, Oxford Biomedica’s Chief Executive Officer,… Read More
Notice of Interim Results
London, UK – 1 September 2021: Oxford Biomedica plc (LSE:Oxford Biomedica), a leading gene and cell therapy group, will be announcing its interim results for the six months ended 30 June 2021 on Wednesday 22 September 2021. A briefing for analysts will be held at 13:00 BST / 08:00 EST… Read More